Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
MRNA • Stock • Health Care / Biotechnology
Current Price
$190.01
+0.57%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
MRNA's evidence points supportive across the available windows.
Generated 2026-10-05T11:30:00.000Z • Evidence 48badf79
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
4
Opposing articles
0
Neutral articles
11
Confidence basis
Supporting evidence
• MRNA Looks 490.4% Overvalued on GF Value™ as August Rally Peaks
• Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
• Moderna (MRNA) Q2 2026 Earnings Call Transcript
• MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
Opposing evidence
No opposing articles were found in this window.
Catalysts
• Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?
• Moderna (MRNA) Q2 2026 Earnings Call Transcript
Risks
No specific risk mentions were identified in this window.
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (4) grows relative to opposing evidence (0) in this window.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (4) in this window.
Showing 8 of 15 sources
MRNA Looks 490.4% Overvalued on GF Value™ as August Rally Peaks
gurufocus.com • 2026-08-28 • Bullish
View source →Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial
insidermonkey.com • 2026-08-28 • Neutral
View source →Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial
finance.yahoo.com • 2026-08-28 • Mixed
View source →Moderna (MRNA) Stock Falls 24% After Cancer-Vaccine Surge
financefeeds.com • 2026-08-21 • Mixed
View source →Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Benzinga • 2026-08-19 • Bullish
Open via Finnhub →Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
Yahoo • 2026-08-11 • Neutral
Open via Finnhub →